Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 7/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19103685 | 0.98 | FKBP1A (0.40) | FKBP1ACA1CA2POLBTSHR | |
| SCHEMBL18355284 | 0.93 | GAA (0.38) | FKBP1ACA1CA2POLBTSHR | |
| SCHEMBL11930025 | 0.80 | L3MBTL1 (0.39) | POLBTSHRKMT2ACYP3A4USP2 | |
| SCHEMBL20988346 | 0.79 | FKBP1A (0.39) | FKBP1ACA1CA2POLBTSHR | |
| SCHEMBL18595665 | 0.79 | HTT (0.44) | FKBP1ACA1CA2POLBTSHR | |
| SCHEMBL6848706 | 0.78 | KDM4E (0.42) | TSHRKMT2ALMNACYP3A4CYP2C9 | |
| SCHEMBL20988341 | 0.78 | CA12 (0.48) | POLBTSHRGAAALDH1A1L3MBTL1 | |
| SCHEMBL20988345 | 0.77 | FKBP1A (0.36) | FKBP1ACA1CA2POLBTSHR | |
| SCHEMBL20988225 | 0.77 | HTT (0.42) | FKBP1ACA1CA2POLBTSHR | |
| SCHEMBL19257390 | 0.77 | HTT (0.37) | FKBP1ACA1CA2POLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240026358-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-01-25 | — | — | US | disclosed |
| US-20230203484-A1 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
| US-10654802-B2 | Indoline derivatives and method for using and producing the same | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNVERSIT (US) | 2020-05-19 | — | — | US | disclosed |
| US-20190135746-A1 | INDOLINE DERIVATIVES AND METHOD FOR USING AND PRODUCING THE SAME | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNVERSITY OF ARIZONA | 2019-05-09 | — | — | US | disclosed |
| US-10022387-B2 | Aza-heteroaryl compounds as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2018-07-17 | — | — | US | disclosed |
| US-10022387-B2 | Aza-heteroaryl compounds as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170232016-A1 | AZA-HETEROARYL COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION | 2017-08-17 | — | — | US | disclosed |
| US-20170232016-A1 | AZA-HETEROARYL COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION | 2017-08-17 | — | — | US | disclosed |
| US-9586949-B2 | Aza-heteroaryl compounds as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2017-03-07 | — | — | US | disclosed |
| US-9586949-B2 | Aza-heteroaryl compounds as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2017-03-07 | — | — | US | disclosed |
| US-20160229843-A1 | AZA-HETEROARYL COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION | 2016-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10654802-B2 | Indoline derivatives and method for using and producing the same | IDO1, IDO2, MMP1 | FKBP1A 39/4885CA1 4143/4885CA2 3337/4885 |
| US-20170232016-A1 | AZA-HETEROARYL COMPOUNDS AS PI3K-GAMMA INHIBITORS | PIK3R5, PIK3R1, PIK3R3 | FKBP1A 2952/4885CA1 4336/4885CA2 3793/4885 |
| US-20190135746-A1 | INDOLINE DERIVATIVES AND METHOD FOR USING AND PRODUCING THE SAME | IDO1, INMT, MMP1 | FKBP1A 35/4885CA1 4298/4885CA2 3607/4885 |
| US-20160229843-A1 | AZA-HETEROARYL COMPOUNDS AS PI3K-GAMMA INHIBITORS | PIK3R5, PIK3R1, PIK3R3 | FKBP1A 2952/4885CA1 4336/4885CA2 3793/4885 |
| US-10022387-B2 | Aza-heteroaryl compounds as PI3K-gamma inhibitors | PIK3R5, PIK3R1, PIK3R3 | FKBP1A 2952/4885CA1 4336/4885CA2 3793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.